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A B S T R A C T
Purpose
Trastuzumab emtansine (T-DM1), an antibody–drug conjugate comprising the cytotoxic agent
DM1, a stable linker, and trastuzumab, has demonstrated substantial activity in human epidermal
growth factor receptor 2 (HER2) –positive metastatic breast cancer, raising interest in evaluating
the feasibility and cardiac safety of T-DM1 in early-stage breast cancer (EBC).
Patients and Methods
Patients (N  153) with HER2-positive EBC and prechemotherapy left ventricular ejection fraction
(LVEF)  55% received (neo)adjuvant doxorubicin plus cyclophosphamide or fluorouracil plus
epirubicin plus cyclophosphamide followed by T-DM1 for four cycles. Patients could then receive
three to four cycles of optional docetaxel with or without trastuzumab. T-DM1 was then resumed
with optional radiotherapy (sequential or concurrent) for 1 year (planned) of HER2-directed therapy.
The coprimary end points were rate of prespecified cardiac events and safety.
Results
Median follow-up was 24.6 months. No prespecified cardiac events or symptomatic congestive
heart failures were reported. Four patients (2.7%) had asymptomatic LVEF declines ( 10
percentage points from baseline to LVEF 50%), leading to T-DM1 discontinuation in one patient.
Of 148 patients who received  one cycle of T-DM1, 82.4% completed the planned 1-year
duration of HER2-directed therapy. During T-DM1 treatment, 38.5% and 2.7% of patients
experienced grade 3 and 4 adverse events, respectively. Approximately 95% of patients receiving
T-DM1 plus radiotherapy completed  95% of the planned radiation dose with delay  5 days.
Conclusion
Use of T-DM1 for approximately 1 year after anthracycline-based chemotherapy was feasible and
generally well tolerated by patients with HER2-positive EBC, providing support for phase III trials
of T-DM1 in this setting.
J Clin Oncol 33:1136-1142. © 2015 by American Society of Clinical Oncology
INTRODUCTION
Human epidermal growth factor receptor 2 (HER2)
is overexpressed in 15% to 20% of breast cancers.1-3
HER2-positive tumors have an aggressive pheno-
type and, before the advent of HER2-directed
therapy, were associated with increased mortality
and shorter time to relapse than HER2-normal
tumors.1,4-6 The HER2-targeted humanized mono-
clonal antibody trastuzumab plus chemotherapy
became standard care for the adjuvant treatment of
HER2-positive early-stage breast cancer (EBC) after
phase III studies showed significantly improved
disease-free and overall survival (OS) rates versus
chemotherapy alone.7-9 In EBC, trastuzumab is of-
ten administered with concurrent radiotherapy
postsurgery10 and/or hormonal therapy (when indi-
cated). Although trastuzumab-based chemotherapy
regimens improve clinical outcome in EBC,7-9,11
they can be associated with significant toxicity re-
sulting from the cytotoxic effects of chemotherapy
on normal cells. Furthermore, some patients de-
velop disease recurrence. Thus, more effective and
less toxic treatments are desired.
Trastuzumab emtansine (T-DM1) is an
antibody–drug conjugate composed of the cyto-
toxic agent DM1 and trastuzumab joined by a stable
thioether linker.12 T-DM1 delivers DM1 directly to
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HER2-overexpressing tumor cells, inhibiting microtubule function
and leading to cell death.12,13 Like trastuzumab, T-DM1 inhibits
HER2 signaling, prevents HER2 shedding, and induces antibody-
dependent cellular cytotoxicity.14 In studies of HER2-positive meta-
static breast cancer (MBC), T-DM1 was well tolerated, with fewer of
the toxicities typically associated with conventional chemotherapy
(eg, alopecia, neutropenia).15-18 In randomized studies, T-DM1 was
associated with longer median progression-free survival (PFS)15,17,18
and OS17 versus chemotherapy plus HER2-directed therapy. Overall
rates of grade3 adverse events (AEs) and treatment discontinuation
because of AEs were lower with T-DM1 than control regimens. How-
ever, rates of grade 3 thrombocytopenia and increased serum ami-
notransferases were greater with T-DM1.15,17,18 Single-agent T-DM1
is approved in the United States19 and European Union for previously
treated HER2-positive MBC.
Given the significant efficacy and favorable safety of T-DM1 in
MBC, there is interest in exploring T-DM1 in EBC. In the neoadjuvant
or adjuvant setting, T-DM1 could potentially replace trastuzumab
plus taxane. Because DM1 is targeted directly to HER2-overexpressing
cells, T-DM1 may allow exposure to cytotoxic therapy for longer (eg, 1
year) than is possible with conventional systemic chemotherapy.
Trastuzumab, the targeting antibody of T-DM1, can be associated
with cardiotoxicity (particularly when part of anthracycline-based
regimens).20-22 Thus, the frequency and severity of cardiac dysfunc-
tion with T-DM1 should be assessed in EBC, where long-term survival
is expected.9,23,24
TDM4874g (BO22857) was a single-arm, open-label, phase II
study that examined the cardiac safety, efficacy, and overall feasibility
of T-DM1 treatment for approximately 1 year after administration of
anthracycline-based chemotherapy in the (neo)adjuvant setting in
HER2-positive EBC. T-DM1 administered concurrently with adju-
vant radiotherapy and/or hormonal therapy was also investigated.
PATIENTS AND METHODS
Study Design and Patients
Eligible patients had EBC, with centrally confirmed HER2-positive status
(in situ hybridization positive or immunohistochemistry 3), Eastern Coop-
erative Oncology Group performance status of 0 or 1, and prechemotherapy
left ventricular ejection fraction (LVEF)  55%. Key exclusion criteria were
stage IV or bilateral breast cancer; prior radiotherapy, immunotherapy, or
biotherapy 5 years before enrollment; history of cardiotoxic chemotherapy;
or active cardiac history (eg, unstable angina, congestive heart failure [CHF],
or myocardial infarction within previous 12 months; high-risk uncontrolled
arrhythmias; clinically significant valvular disease; or uncontrolled hyperten-
sion). All patients provided written informed consent.
Patients received four cycles of (neo)adjuvant doxorubicin plus cyclo-
phosphamide (AC) or three to four cycles of fluorouracil plus epirubicin plus
cyclophosphamide (FEC) followed by four cycles of T-DM1 3.6 mg/kg. After
the first four T-DM1 cycles, patients could receive an optional three to four
cycles of docetaxel with or without trastuzumab at the treating physician’s
discretion (Fig 1). Use of trastuzumab and docetaxel was permitted in this
curative patient population, because the efficacy of T-DM1 compared with the
standard of care (ie, trastuzumab plus chemotherapy) was not established.
Sequential or concurrent radiotherapy could be provided after the first four
cycles of T-DM1 and optional docetaxel with or without trastuzumab; sequen-
tial radiotherapy could be administered with or without trastuzumab. The
safety of concurrent T-DM1 and radiotherapy was evaluated in the first 20
patients before others were treated. Patients continued T-DM1 for a planned
17 cycles of HER2-directed therapy (total number of T-DM1 and trastuzumab
cycles). Hormonal therapy was permitted in patients with hormone receptor–
positive disease after having completed four T-DM1 cycles and optional do-
cetaxel with or without trastuzumab. Patients were enrolled before or after
completion of AC/FEC (Fig 1). The trial adhered to the Declaration of Hel-
sinki, Good Clinical Practices, and applicable local laws.
Study Assessments
LVEF was evaluated by echocardiogram or multiple-gated acquisition
scans at baseline, at the end of anthracycline-based treatment, after cycles two
and four of T-DM1 and every four cycles of T-DM1 thereafter, before and after
the start of new treatment, at the end of T-DM1 treatment (if 6 weeks since
last scan), and at 3- and 6-month follow-up visits (Fig 1). The same method of
LVEF evaluation was to be used throughout. Laboratory assessments and
physical examinations were conducted at baseline and at subsequent visits
until the study-termination or end-of-treatment visit.
AEs were mapped to terms from the Medical Dictionary for Regula-
tory Activities and graded per National Cancer Institute Common Termi-
nology Criteria for Adverse Events (version 4.0). Laboratory abnormalities
were defined per established normal ranges and National Cancer Institute
Common Terminology Criteria for Adverse Events (version 4.0). Serious
AEs were life threatening or fatal, resulted in or prolonged hospitalization,
resulted in significant disability, or were considered by the investigator to
be medically significant.
T-DM1 Dose Modifications
Toxicity was assessed before each T-DM1 dose; if the results from clinical
assessment and laboratory testing were acceptable, T-DM1 was administered.
If dose reductions were required, T-DM1 was reduced to 3.0 or 2.4 mg/kg; dose
re-escalation was not allowed. T-DM1 was adjusted per a prespecified algo-
rithm in patients experiencing cardiotoxicity (Appendix Fig A1, online only)
and according to protocol guidelines in patients experiencing hematotoxicity,
hepatotoxicity, neurotoxicity, or infusion-related reactions. Patients were
withdrawn if they experienced two consecutive or three intermittent T-DM1
dose delays for asymptomatic LVEF decrease, symptomatic CHF, an inability
to receive T-DM1 after two dose reductions for any reason, a dose delay 42
days from last dose, disease recurrence, or unacceptable toxicity.
Statistical Methods
The coprimary end points were safety and rate of prespecified cardiac
events within the first 12 weeks of T-DM1 treatment. A cardiac event was
defined as death resulting from a cardiac cause or severe CHF (New York
Heart Association [NYHA] class III or IV) accompanied by a decrease in LVEF
of  10 percentage points from baseline to LVEF  50%. Secondary end
points included long-term ( 1 year) cardiac and overall safety, feasibility of
administering T-DM1 concurrent with radiotherapy, feasibility of the planned
duration of T-DM1 (17 cycles of HER2-directed therapy), and pathologic
complete response (pCR) rate for patients administered preoperative T-DM1.
pCR was defined as the absence of invasive neoplastic cells on microscopic
examination of the original breast tumor area and axillary lymph nodes (ypT0/
is, ypN0) after primary systemic therapy and surgery.
Patients who received one dose of T-DM1 were evaluable for overall
safety. Patients who received one dose of T-DM1 and underwent an echo-
cardiogram/MUGA assessment by 12 weeks from first T-DM1 dose or discon-
tinued the study because of per-protocol cardiac events before completing four
T-DM1 cycles were evaluable for protocol-prespecified cardiac safety.
The sample size was chosen to ensure a reasonable probability of detect-
ing cardiac events, which were expected to occur at a relatively low rate per
prior trastuzumab studies.20-22 Observing a cardiac event in  five patients
among the first 60 cardiac safety–evaluable patients or in  eight patients
among 120 cardiac safety–evaluable patients would result in study termina-
tion. It was assumed that  90% of participants would complete AC/FEC
without disease progression or excessive toxicity and would receiveone dose
of T-DM1. Under this assumption, approximately 135 patients were needed to
achieve 120 cardiac safety–evaluable patients, with whom the 90% confidence
limits would be within 8% of the observed cardiac event rate. During the
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actual analysis, the exact 95% CI of protocol-prespecified cardiac events,
calculated using the Blyth-Still-Casella method, was provided.
RESULTS
In total, 153 patients from 35 sites were enrolled between October
2010 and June 2011 (Fig 2). As of June 12, 2013, median follow-up was
24.6 months (range, 0.2 to 29.0 months). Baseline demographic and
clinical characteristics were similar between patients in the adjuvant
(n 99) and neoadjuvant settings (n 54; Table 1).
Drug Exposure and Treatment Duration
In the intent-to-treat population (N 153), 38 patients (24.8%)
received optional docetaxel, 74 (48.4%) received optional trastu-
zumab, and 116 (75.8%) received radiotherapy (concurrent, n 39;
sequential, n  77; Table 2). Among the 74 patients who received
trastuzumab, 36 also received docetaxel, and 68 also received radio-
therapy. Sixty-two patients (40.5% of intent-to-treat population) re-
ceived concurrent hormonal therapy with T-DM1; others may have
received hormonal therapy after T-DM1 treatment. Of the 148 pa-
tients who received  one cycle of T-DM1, 82.4% (n  122) com-
pleted the planned duration (approximately 1 year) of HER2-directed
therapy (Table 2). Patients received a median of 14 cycles of T-DM1
(range, one to 17), with 75.7% (n 112) receiving 13 cycles.
Twenty (13.5%) of the 148 patients who received one cycle of
T-DM1 experienced AEs leading to T-DM1 discontinuation, most
commonly thrombocytopenia (n 5; grade 2), neutropenia (n 2;
grade 3), and increased AST (n2; one grade 2, one grade 3). T-DM1
dose was reduced to 3.0 mg/kg in 27 patients (18.2%) and to 2.4 mg/kg
in five (3.4%). The most common reasons for T-DM1 dose reduction
were grade 3 increases in ALT (n 8) and AST (n 6). T-DM1 dose
was reduced to 3.0 mg/kg most often at cycle two (n 7) and to 2.4
mg/kg most often at cycle 10 (n 2).
Of those who received T-DM1 concurrently with radiother-
apy and for whom radiotherapy dose information was available,
94.7% (36 of 38 patients) completed 95% of the planned radio-
therapy dose with delay 5 days (Table 2). This was similar to the
96.1% (74 of 77 patients) completion rate among those who re-
ceived sequential radiotherapy.
Cardiac Safety
No protocol-prespecified cardiac events (95% CI, 0% to 2.45%)
or symptomatic CHF events were reported after T-DM1 treatment
(Table 3). Five patients (3.4%) experienced cardiac AEs that the inves-
tigator suspected were related to T-DM1. Four patients (2.7%) expe-
rienced asymptomatic LVEF declines ( 10 percentage points from
baseline to LVEF 50%). One of these patients, with a postanthracy-
cline LVEF of 50%, discontinued T-DM1 with an LVEF of 45%. LVEF
Baseline
LVEF
assessment
Optional 
sequential RT† 
± trastuzumab
T-DM1 for up to 17 cycles 
of HER2-directed therapy
total
Optional 
concurrent RT  
T-DM1 for up to 17 cycles of HER2-directed
therapy total
After
cycle 2
After 
chemotherapy
After
cycle 4
After optional
chemotherapy
HER2-positive
early-stage 
breast cancer
AC × 4 cycles
or
FEC × 3 or 4
cycles*
T-DM1
× 4 cycles
Optional docetaxel 
× 3 or 4 cycles ±
trastuzumab × 9 or
12 weeks
After every fourth cycle, at end of study,
and at 3- and 6-month follow-ups
Chemotherapy
     AC, A: 60 mg/m2, C: 600 mg/m2, q2w or q3w
     FEC, F: 500 mg/m2, E: 100 mg/m2, C: 600 mg/m2, q3w
     Docetaxel, 75 or 100 mg/m2, q3w
T-DM1 (3.6 mg/kg q3w)
Trastuzumab (8 mg/kg loading, 6 mg/kg maintenance q3w or 4 mg/kg loading, 2 mg/kg maintenance qw)
RT
Surgery in the
adjuvant setting
Surgery in the 
neoadjuvant setting
†
‡§
‡§
‡
Fig 1. TDM4874g study design. AC, doxorubicin plus cyclophosphamide; FEC, fluorouracil plus epirubicin plus cyclophosphamide; HER2, human epidermal growth
factor receptor 2; LVEF, left ventricular ejection fraction; qw, once every week; q2w, once every 2 weeks; q3w, once every 3 weeks; RT, radiotherapy; T-DM1,
trastuzumab emtansine. (*) Enrollment in adjuvant or neoadjuvant setting and choice of AC or FEC was at discretion of investigator; patients were allowed to enroll
either before or after completion of AC or FEC. (†) Radiotherapy was per investigator discretion; safety was evaluated after first 20 patients had been treated with
concurrent T-DM1 and RT, and additional patients were administered sequential RT with or without trastuzumab until confirmation of concurrent T-DM1 and RT safety.
(‡) Dose reductions to 3.0 and 2.4 mg/kg were permitted for toxicity. (§) Maximum number of T-DM1 cycles was determined as number of cycles to complete
approximately 1 year of HER2-directed therapy, including any periods of optional trastuzumab.
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for this patient had recovered to 50% at last follow-up (14 months
after last T-DM1 dose). The other three LVEF declines were unrelated
to T-DM1 per the investigator, with two occurring during treatment
with optional docetaxel plus trastuzumab. No patient had an LVEF
40% at any time during the study. Mean LVEF was stable throughout
T-DM1 treatment (Appendix Fig A2, online only).
Overall Safety
During T-DM1 therapy (n 148), the most common any-grade
AEs were nausea (37.8%; n56) and headache (37.2%; n55; Table
4). Fifty-seven patients (38.5%) experienced grade 3 AEs, and four
(2.7%) experienced grade 4 AEs; there were no grade 5 AEs. The most
common grade  3 AEs were thrombocytopenia (8.1%; n  12),
increased ALT (7.4%; n  11), and increased AST (7.4%; n  11;
Table 4). Fifteen patients (10.1%) experienced serious AEs during
T-DM1 therapy, with atrial fibrillation (n 2), pyrexia (n 2), and
device-related infection (n  2) occurring in  one patient. No
patient met Hy’s law laboratory criteria for hepatotoxicity ( three-
fold increase in ALT or AST above upper limit of normal and 
two-fold increase in bilirubin above upper limit of normal)25; nodular
regenerative hyperplasia and portal hypertension were not reported.
During concurrent T-DM1 and hormonal therapy (n 62), the
rate of any-grade AEs was 69.4% (n 43); the rate of grade 3 AEs was
12.9% (n 8); no grade 4 AEs were reported. Neutropenia (n 2)
was the only grade 3 AE reported in  two patients administered
concurrent hormonal therapy.
During concurrent T-DM1 and radiotherapy (n  39), three
patients (7.7%) had grade 3 AEs (one each: neutropenia, asthenia,
erythema), and one patient (2.6%) experienced radiotherapy-
associated pneumonitis (grade 2). During sequential radiotherapy
(n 77), two patients (2.6%) had grade 3 AEs (neutropenia, radio-
therapy pneumonitis), and one additional patient had grade 2 radio-
therapy pneumonitis; thus, in total, 2.6% of patients experienced
radiotherapy-associated pneumonitis. No grade 4 AEs were reported
during concurrent or sequential radiotherapy.
Patients with HER2-positive EBC
   Adjuvant treatment
   Neoadjuvant treatment
(N = 153)
(n = 99)
(n = 54)
Patients who completed the study
Patients who discontinued the study early
   Adverse event
   Lost to follow-up
   Noncompliance to protocol requirements
   Patient/guardian decision to withdraw
   Other
(n = 130)
(n = 23)
   (n = 9)
   (n = 1)
  (n = 2)
   (n = 6)
   (n = 5)
Investigational period 2
Started T-DM1 from cycle 5
Completed T-DM1 investigational period 2
Investigational period 1
Started T-DM1
Completed first 4 cycles of T-DM1
RT as indicated
Received concurrent RT
Received sequential RT ± trastuzumab
Chemotherapy period 2 (optional)
Completed docetaxel ± trastuzumab
(n = 140)
(n = 122)
(n = 148)
(n = 143)
(n = 39)
(n = 77)
(n = 38)
Enrolled after chemotherapy 
period 1
   Adjuvant treatment
   Neoadjuvant treatment
Chemotherapy period 1
   Started AC/FEC treatment
   Completed AC/FEC treatment
  (n = 106)
 (n = 104)
Enrolled before chemotherapy )74 = n()601 = n(
period 1
   Adjuvant treatment
   Neoadjuvant treatment
(n = 31)
(n = 16)
(n = 68)
(n = 38)
Fig 2. Flow diagram of patients in TDM4874g. AC, doxorubicin plus cyclophos-
phamide; EBC, early-stage breast cancer; FEC, fluorouracil plus epirubicin plus
cyclophosphamide; HER2, human epidermal growth factor receptor 2; RT,
radiotherapy; T-DM1, trastuzumab emtansine.
Table 1. Selected Baseline Demographic and Clinical Characteristics
Characteristic
Adjuvant
Setting
(n  99)
Neoadjuvant
Setting
(n  54)
All Patients
(N  153)
No. % No. % No. %
Age, years
18-40 13 13.1 9 16.7 22 14.4
41-64 72 72.7 41 75.9 113 73.9
 65 14 14.1 4 7.4 18 11.8
Race/ethnicity
White 67 67.7 34 63.0 101 66.0
Black or African
American 1 1.0 1 1.9 2 1.3
Asian 6 6.1 8 14.8 14 9.2
Multiple 1 1.0 0 0 1 0.7
Not available 24 24.2 11 20.4 35 22.9
World region
Europe 76 76.8 34 63.0 110 71.9
United States 19 19.2 13 24.1 32 20.9
Asia 4 4.0 7 13.0 11 7.2
ECOG PS
0 89 89.9 49 90.7 138 90.2
1 10 10.1 5 9.3 15 9.8
ER/PR status
ER positive and/or PR
positive 65 65.7 30 55.6 95 62.1
ER negative and PR
negative 34 34.3 24 44.4 58 37.9
Prechemotherapy LVEF
by local
assessment, %
Median 69.0 65.0 67.0
Range 52-79 55-81 52-81
 60 92 92.9 45 83.3 137 89.5
55 to  60 6 6.1 9 16.7 15 9.8
 55 1 1.0 0 0 1 0.7
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance
status; ER, estrogen receptor; LVEF, left ventricular ejection fraction; PR,
progesterone receptor.
One patient had prechemotherapy LVEF of 52% and was enrolled onto
study in postchemotherapy setting, with postchemotherapy LVEF of 64%.
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Efficacy
The pCR (ypT0/isN0) rate was 56.0% (28 of 50 patients; 95%
CI, 41.3% to 69.6%) in those who were administered neoadjuvant
therapy (anthracycline followed by four T-DM1 cycles) and under-
went surgery. The pCR rate was 51.7% (15 of 29 patients; 95% CI,
33.9 to 70.1) in those with hormone receptor–positive disease and
61.9% (13 of 21 patients; 95% CI, 39.8 to 80.3) in those with
hormone receptor–negative disease. One patient who was treated
in the neoadjuvant setting discontinued T-DM1 because of disease
progression before surgery.
DISCUSSION
In this study, the first to our knowledge to evaluate T-DM1 in patients
with EBC, approximately 1 year of (neo)adjuvant T-DM1 after
anthracycline-based chemotherapy was feasible and generally well
tolerated. Only 17.6% of patients who initiated treatment with
T-DM1 did not complete the planned therapy duration. In compari-
son, 31.4% discontinued trastuzumab before completing 1 year of
therapy in the joint analysis of the NSABP B-31 (National Surgical
Adjuvant Breast and Bowel Project) trial and NCCTG N9831 (North
Table 2. Drug Exposure and Duration
Drug Exposure
Patients Cycles
No. % Median Range
All patients (N  153)
Anthracycline-based regimens 152 99.3 — —
AC 68 44.4 4 4-4
FEC 84 54.9 3 1-4
Docetaxel 38 24.8 4 1-4
Trastuzumab 74 48.4 4 1-10
T-DM1 148† 96.7 14 1-17
Hormonal therapy 62 40.5 — —
T-DM1–treated patients (n  148)†
Completed planned duration of T-DM1 122 82.4 — —
Completed planned duration without
dose reduction 98 66.2 — —
Dose reduced to 3.0 mg/kg 27 18.2 — —
Dose reduced to 2.4 mg/kg 5 3.4 — —
Early discontinuation
AE 20 13.5‡ — —
PD 1 0.7 — —
Other 5 3.4§ — —
RT-treated patients 116 75.8 — —
Concurrent RT (n  38) — —
Completed  95% of planned RT
dose with  5-day delay 36 94.7 — —
Sequential RT (n  77)
Completed  95% of planned RT
dose with  5-day delay 74 96.1 — —
Abbreviations: AC, doxorubicin plus cyclophosphamide; AE, adverse event;
FEC, fluorouracil plus epirubicin plus cyclophosphamide; PD, progressive
disease; RT, radiotherapy; T-DM1, trastuzumab emtansine.
One additional patient received four cycles of AC before enrollment, but
detailed dosing information was incomplete.
†Five patients did not receive T-DM1 because of elevated liver function tests
after neoadjuvant chemotherapy (n 1), PD during neoadjuvant chemother-
apy (n  1), patient/legal guardian decision to withdraw (n  1), and
discontinuation of FEC (n  2).
‡Thrombocytopenia (n  5); neutropenia and increased AST (n  2 each);
vertigo, reduced visual acuity, fatigue, malaise, pyrexia, hyperbiliru-
binemia, increased ALT, increased blood bilirubin, decreased ejection
fraction, joint crepitation, muscle spasms, myalgia, and peripheral neu-
ropathy (n  1 each).
§Patient/legal guardian decision to discontinue (n  4); noncompliance with
protocol requirements (n  1).
One patient did not have available RT dose information and thus was not
included in this section of table.
Table 3. Summary of Cardiac Safety
Cardiac Event
T-DM1–Treated
Patients
(n  148)
No. %
Protocol-prespecified cardiac event 0 0.0
Symptomatic CHF event 0 0.0
Asymptomatic LVEF decline 4 2.7
T-DM1 discontinuation because of cardiac
dysfunction 1 0.7†
T-DM1–related cardiac disorder 5 3.4
Atrial fibrillation (grade 4) 1 0.7
Tricuspid valve incompetence (grade 2) 1 0.7
Palpitations (all grade 1) 4 2.7
Supraventricular extrasystoles (grade 2) 1 0.7
Abbreviations: CHF, congestive heart failure; LVEF, left ventricular ejection
fraction; T-DM1, trastuzumab emtansine.
LVEF decline of  10 percentage points from baseline to  50%. Three
were considered by investigators to be unrelated to T-DM1; two of these
events occurred during treatment with trastuzumab.
†With LVEF of 45%, last LVEF after discontinuation was 50%.
Table 4. Summary of AEs Among T-DM1–Treated Patients During
Treatment With T-DM1 (n  148)
AE
Any-Grade AEs Occurring in  15% of
Patients
Any Grade Grade 3
No. % No. %
Nausea 56 37.8 0 0.0
Headache 55 37.2 1 0.7
Epistaxis 47 31.8 2 1.4
Asthenia 45 30.4 2 1.4
Pyrexia 39 26.4 1 0.7
Fatigue 34 23.0 3 2.0
Arthralgia 33 22.3 0 0.0
Thrombocytopenia 32 21.6 12 8.1
Myalgia 31 20.9 1 0.7
Vomiting 25 16.9 0 0.0
Rash 24 16.2 0 0.0
Grade 3 AEs Occurring in  2% of Patients
Any Grade Grade 3
No. % No. %
Thrombocytopenia 32 21.6 12 8.1
Increased AST 19 12.8 11 7.4
Increased ALT 18 12.2 11 7.4
Neutropenia 15 10.1 8 5.4
Hypertension 8 5.4 4 2.7
Abbreviations: AE, adverse event; T-DM1, trastuzumab emtansine.
Total of five grade 4 AEs were reported in four T-DM1–treated patients while
receiving treatment with T-DM1: febrile neutropenia (n  1) and pancyto-
penia (n 1; same patient), atrial fibrillation (n 1), decreased platelet count
(n  1), and hypokalemia (n  1).
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Central Cancer Treatment Group) trial.8 However, in the HERA
(Herceptin Adjuvant) study of patients with HER2-positive EBC who
completed locoregional therapy and received four cycles of (neo)
adjuvant chemotherapy, only 8.5% did not complete 1 year of treat-
ment with single-agent trastuzumab.7
The sample size of our study was chosen to ensure a reasonable
probability of detecting cardiac events; however, no patient experi-
enced a prespecified cardiac event or symptomatic CHF. Although the
sample size of our study was relatively small (n148), and the patient
population was heterogeneous, with patients having different treat-
ment exposures, the rate of NYHA class III or IV CHF was numerically
lower than that reported in pivotal trials of adjuvant trastuzumab,
where an incidence of 2.3% to 3.8% was observed in patients admin-
istered adjuvant trastuzumab plus taxane after anthracycline-based
chemotherapy.23 The rate of NYHA class III or IV CHF in the HERA
trial, in which patients were administered adjuvant trastuzumab after
chemotherapy, was 0.60%.26
In our study, 2.7% of patients experienced asymptomatic
declines in LVEF ( 10 percentage points from baseline to LVEF
50%). Cross-trial comparison of the incidence of asymptomatic
LVEF decline is difficult because of variations in how this event is
defined and differences in prior treatment exposure and popula-
tion characteristics. However, HERA used the same definition of
asymptomatic LVEF decline as our study. In HERA, in which
patients received single-agent trastuzumab after locoregional ther-
apy and four cycles of (neo)adjuvant chemotherapy, the rate of
asymptomatic LVEF decline was 7.1% (although baseline was re-
corded after anthracycline treatment).7 In NSABP B-31, the inci-
dence of LVEF declines 10% to 55% was 34% in the AC plus
paclitaxel plus trastuzumab arm.27 In the BCIRG (Breast Cancer
International Research Group) 006 trial, the subclinical loss of
mean LVEF ( 10% relative loss) was 18.6% in the AC plus
paclitaxel plus trastuzumab arm versus 9.4% in the docetaxel plus
carboplatin plus trastuzumab arm.9 Most cardiac events in these
and other studies occurred during active anti-HER2 therapy. With
 8 years of follow-up, cardiac event rates did not increase signif-
icantly.9,22,28,29 Thus, we do not expect the cardiac event rate in our
study would increase with longer follow-up.
The cardiac safety profile of T-DM1 in our study was similar to
that reported in other studies of T-DM1 in patients with HER2-
positive MBC. Only one patient, who had a postanthracycline LVEF of
50%, experienced an asymptomatic LVEF decline that was considered
related to T-DM1; although LVEF in this patient declined to 45%, it
had recovered to 50% when the patient was assessed approximately 14
months after the last T-DM1 dose. In a pooled analysis of six phase I to
III clinical trials (n  882), four patients (0.5%) had a postbaseline
LVEF 40%, and 16 (1.8%) had an LVEF decline 15 percentage
points from baseline to 50%.16 In the phase III TH3RESA study of
patients with HER2-positive MBC previously treated with  two
HER2-directed therapies for MBC, 1.5% of T-DM1–treated patients
experienced declines in LVEF of15 percentage points from baseline
to 50%—similar to the rate observed in the treatment of physi-
cian’s choice control arm (1.1%).18 Moreover, T-DM1 had no
clinically significant effect on the corrected QT interval in a dedi-
cated phase II study of patients with previously treated HER2-
positive MBC.30
The overall safety profile of T-DM1 in EBC was also similar to
that seen in phase III studies of T-DM1 in MBC, with the most
commonly reported grade  3 AEs being thrombocytopenia
(8.1%), increased AST (7.4%), and increased ALT (7.4%). The
corresponding rates in the EMILIA trial were 12.9%, 4.3%, and
2.9%, respectively.17 In TH3RESA, these incidences were 4.7%,
2.2%, and  2%, respectively.18 In our study, 2.6% of patients
administered T-DM1 concurrent with or sequential to radiother-
apy experienced pneumonitis versus 1.1% in the trastuzumab-
containing arms and 0.6% in the chemotherapy-only arm of the
NCCTG N9831 study.10 Among patients receiving sequential
treatment, no minimum period was required to have elapsed be-
tween the completion of radiotherapy and the initiation of T-DM1
in our study, and the extent of radiotherapy was per investigator
discretion. Considering the relatively small study sample size and
the low frequency of pneumonitis overall, larger sample sizes are
needed to fully establish the overall safety profile of T-DM1 in the
EBC setting, including in patients receiving T-DM1 and radiother-
apy.
The overall rate of cardiac events in this heterogeneous patient
population was low, suggesting that T-DM1 may provide a potentially
less toxic alternative to treatment with conventional chemotherapy
plus trastuzumab in patients with EBC and that phase III trials of
T-DM1 in this setting are warranted. If validated in phase III studies,
the favorable tolerability of T-DM1 may allow use of targeted cyto-
toxic therapy for a longer duration (eg, 1 year) than is feasible with
conventional cytotoxic agents. Three randomized phase III studies of
T-DM1 in HER2-positive EBC have begun: KATHERINE (BO27938;
ClinicalTrials.gov No. NCT01772472) compares adjuvant T-DM1
with trastuzumab in patients with residual invasive tumors after pre-
operative therapy and surgery; KAITLIN (BO28407; ClinicalTrials
.gov No. NCT01966471) compares T-DM1 plus pertuzumab with
trastuzumab plus pertuzumab plus taxane after an adjuvant anthracy-
cline regimen; and KRISTINE (BO28408; ClinicalTrials.gov No.
NCT02131064) examines neoadjuvant T-DM1 plus pertuzumab ver-
sus neoadjuvant trastuzumab plus pertuzumab plus docetaxel plus
carboplatin. These studies will provide further understanding of the
safety and efficacy of (neo)adjuvant T-DM1 in HER2-positive EBC.
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Repeat LVEF in 3 weeks*
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Fig A1. Algorithm for trastuzumab emtansine (T-DM1) discontinuation based on left ventricular ejection fraction (LVEF) assessments in asymptomatic patients. (*)
Three intermittent holds of T-DM1 led to discontinuation. (†) Baseline refers to prechemotherapy LVEF measurement, regardless of whether patient was enrolled
before or after completing chemotherapy. EF, ejection fraction.
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Fig A2. Mean left ventricular ejection fraction (LVEF) in trastuzumab emtansine (T-DM1) –treated patients over time. (*) Optional trastuzumab could have been
administered between cycles four and eight.
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